Skip to main content

Table 5 Quantitative comparison of antimicrobial prescriptions before and after NTM acquisition

From: Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis

   Patients with Slow-growing NTM (N = 17) Patients with Rapidly Growing NTM (N = 8)
  Before After    Before After  
N Median (range) Median (range) P-value N Median (range) Median (range) P-value
Penicillins/Beta lactamase 12 0.5 (0–3) 4 (0–9) 0.010 4 1.5 (0.2) 1.5 (1.6) 0.65/0.41
Cephalosporin 5 2 (0–5) 1 (0–2) 0.99 2 1 (0–2) 13.5 (0–27) 0.66
Glycopeptide a 1 0 2
Carbapenems 3 0 (0–0) 2 (1–8) 0.11 2 0.5 (0–1) 5.5 (0–11) 0.66
Monobactam b 2 0.5 (0–1) 0.5 (0–1) 0.99 3 0 (0–0) 2 (1–3) 0.11
Aminoglycosides 11 1 (0–5) 3 (0–10) 0.20 5 2 (0–5) 5 (2–18) 0.18
Macrolides 7 0 (0–0) 5 (1–8) 0.018 5 0 (0–2) 3 (1–17) 0.042
Lincosamides c 2 0 (0–0) 1 (1–1) 0.16 1 1 0 0.32
Oxazolidinones d 1 0 1 0.32 1 0 1 0.32
Fluoroquinolones 9 2 (0–4) 2 (0–4) 0.99 6 0.5 (0–2) 4.5 (0–26) 0.12
Antifolates e 8 1 (0–7) 1 (0–13) 0.40 4 1 (0–4) 2 (1–4) 0.41
Rifamycins f 5 0 (0–0) 5 (2–7) 0.042 0
  1. aVancomycin
  2. bAztreonam
  3. cClindamycin
  4. dLinezolid
  5. eTrimethoprim/sulfonamides
  6. fRifampin
\